18F-FDG PET与DWI数据集预测软组织肉瘤新辅助隔离肢体灌注治疗反应的评估
本研究评估并比较了同时获取的定量18F-FDG PET与扩散加权MRI数据集预测软组织肉瘤对新辅助隔离肢体灌注(ILP)组织病理学反应的能力。37例 extremity STS 患者在ILP前后行18F-FDG PET/MRI,分析肿瘤大小、SUV和ADC值变化。结果显示SUV和ADCmean变化在应答者与非应答者间差异显著(P<0.01),且SUVpeak、SUVmean、ADCmean及ADCmean/SUVpeak比值的AUC较高,提示PET/MRI可用于术前评估和治疗监测。
要点
- SUV和ADCmean变化可显著区分ILP应答者与非应答者(P<0.01)。
- ADCmean/SUVpeak比值的AUC为0.89,预测性能较好。
- 整合PET/MRI有潜力用于STS新辅助治疗的术前评估与监测。
核心结论
- PET和MRI衍生的定量参数(SUV和ADCmean)及其组合在预测STS对新辅助ILP的组织病理学治疗反应方面表现良好。
- 整合PET/MRI可作为STS新辅助治疗策略的术前评估和监测的有价值工具。
研究设计与样本
- 共纳入37例经确认的 extremity STS 患者,在美法仑和肿瘤坏死因子-α的ILP前后行18F-FDG PET/MRI。
- 对每位患者,在治疗前和治疗后检查中测定最大肿瘤大小、代谢活性(SUV)和扩散受限(ADC),并计算治疗期间的百分比变化。
- 采用Mann-Whitney U检验和受试者工作特征分析比较不同定量参数预测组织病理学治疗反应的结果。
- 肿瘤切除后的组织病理学分析结果作为参考标准,根据Salzer-Kuntschik分级量表将患者定义为应答者或非应答者。
主要发现
- 组织病理学分析将22例(59%)患者归类为应答者(I-III级),15例(41%)为非应答者(IV-VI级)。
- 治疗期间,应答者肿瘤显示大小平均缩小-9.7%,代谢活性下降(SUVpeak -51.9%;SUVmean -43.8%),ADC值升高(ADCmin +29.4%;ADCmean +32.8%)。
- 非应答者的百分比变化为:肿瘤大小-6.2%,SUVpeak -17.3%,SUVmean -13.9%,ADCmin +15.3%,ADCmean +14.6%。
- SUV和ADCmean的变化在应答者与非应答者之间差异显著(<0.01),而肿瘤大小和ADCmin的差异不显著(>0.05)。
- 相应的AUC分别为:肿瘤大小0.63,SUVpeak 0.87,SUVmean 0.82,ADCmin 0.63,ADCmean 0.84,ADCmean与SUVpeak比值0.89。
关键数值与推荐
- 应答者定义为Salzer-Kuntschik分级I-III级,非应答者定义为IV-VI级。
- SUV和ADCmean变化在应答者与非应答者间差异显著(P<0.01)。
- ADCmean/SUVpeak比值的AUC为0.89,SUVpeak的AUC为0.87,SUVmean的AUC为0.82,ADCmean的AUC为0.84。
临床怎么用
- 对于接受新辅助ILP的 extremity STS 患者,可利用PET/MRI定量参数(尤其是SUV和ADCmean及其比值)预测组织病理学治疗反应。
- 整合PET/MRI可在术前评估和监测新辅助治疗策略中作为有价值的工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our purpose was to evaluate and compare the clinical utility of simultaneously obtained quantitative 18F-FDG PET and diffusion-weighted MRI datasets for predicting the histopathologic response of soft-tissue sarcoma (STS) to neoadjuvant isolated limb perfusion (ILP). Methods: In total, 37 patients with a confirmed STS of the extremities underwent 18F-FDG PET/MRI before and after ILP with melphalan and tumor necrosis factor-α. For each patient, the maximum tumor size, metabolic activity (SUV), and diffusion restriction (apparent diffusion coefficient, ADC) were determined in pre- and posttherapeutic examinations, and percentage changes during treatment were calculated. Mann-Whitney U testing and receiver-operating-characteristic analysis were used to compare the results of the different quantitative parameters to predict the histopathologic response to therapy. Results from histopathologic analysis after tumor resection served as the reference standard, and patients were defined as responders or nonresponders based on the grading scale by Salzer-Kuntschik. Results: Histopathologic analysis categorized 22 (59%) patients as responders (grades I-III) and 15 (41%) as nonresponders (grades IV-VI). Under treatment, tumors in responders showed a mean reduction in size (-9.7%) and metabolic activity (SUVpeak, -51.9%; SUVmean, -43.8%), as well as an increase of the ADC values (ADCmin, +29.4%; ADCmean, +32.8%). The percentage changes in nonresponders were -6.2% in tumor size, -17.3% in SUVpeak, -13.9% in SUVmean, +15.3% in ADCmin, and +14.6% in ADCmean Changes in SUV and ADCmean significantly differed between responders and nonresponders (<0.01), whereas differences in tumor size and ADCmin did not (>0.05). The corresponding AUCs were 0.63 for tumor size, 0.87 for SUVpeak, 0.82 for SUVmean, 0.63 for ADCmin, 0.84 for ADCmean, and 0.89 for ratio of ADCmean to SUVpeakConclusion: PET- and MRI-derived quantitative parameters (SUV and ADCmean) and their combination performed well in predicting the histopathologic therapy response of STS to neoadjuvant ILP. Therefore, integrated PET/MRI could serve as a valuable tool for pretherapeutic assessment as well as monitoring of neoadjuvant treatment strategies of STS.
引用
- Chodyla M, Demircioglu A, Schaarschmidt BM, et al. Evaluation of 18F-FDG PET and DWI Datasets for Predicting Therapy Response of Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb Perfusion. J Nucl Med. 2020. PMID: 32737246. doi:10.2967/jnumed.120.248260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。